KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Total Current Liabilities: 2012-2025

Historic Total Current Liabilities for Travere Therapeutics (TVTX) over the last 13 years, with Sep 2025 value amounting to $135.1 million.

  • Travere Therapeutics' Total Current Liabilities fell 28.92% to $135.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $135.1 million, marking a year-over-year decrease of 28.92%. This contributed to the annual value of $200.8 million for FY2024, which is 12.84% up from last year.
  • Per Travere Therapeutics' latest filing, its Total Current Liabilities stood at $135.1 million for Q3 2025, which was down 28.74% from $189.5 million recorded in Q2 2025.
  • Travere Therapeutics' Total Current Liabilities' 5-year high stood at $200.8 million during Q4 2024, with a 5-year trough of $85.0 million in Q1 2021.
  • For the 3-year period, Travere Therapeutics' Total Current Liabilities averaged around $161.5 million, with its median value being $173.2 million (2024).
  • The largest annual percentage gain for Travere Therapeutics' Total Current Liabilities in the last 5 years was 56.30% (2025), contrasted with its biggest fall of 28.92% (2025).
  • Travere Therapeutics' Total Current Liabilities (Quarterly) stood at $124.1 million in 2021, then rose by 14.57% to $142.2 million in 2022, then climbed by 25.14% to $177.9 million in 2023, then climbed by 12.84% to $200.8 million in 2024, then decreased by 28.92% to $135.1 million in 2025.
  • Its Total Current Liabilities was $135.1 million in Q3 2025, compared to $189.5 million in Q2 2025 and $182.5 million in Q1 2025.